EGFR and cancer: The recent progresses in the knowledge of cancer biology and drug-resistance mechanisms have identified, among the intracellular signalling pathways, that act as down-stream to the EGFR, the AKT and RAS/RAF/ mitogen-activated protein kinase (MAPK) pathways as major responsible for the development of cancer cell resistance to EGFR inhibitors [2]–[4].